Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis

Neuro Oncol. 2019 Jul 11;21(7):954-955. doi: 10.1093/neuonc/noz071.

Theophilos Tzaridis^{1

2}, Irina Gepfner-Tuma^{3

4}, Sophie Hirsch^{3

4}, Marco Skardelly^{3

4}, Benjamin Bender^{4

5}, Frank Paulsen^{4

6}, Christina Schaub⁴, Johannes Weller¹, Niklas Schäfer¹, Ulrich Herrlinger¹, Ghazaleh Tabatabai^{3

4

7}

¹ Division of Neuro-Oncology, Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany.
² Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
³ Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁴ Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart; Eberhard Karls University Tübingen, Tübingen, Germany.
⁵ Department of Neuroradiology, University Hospital of Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
⁶ Department of Radiation Oncology, University Hospital of Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
⁷ German Consortium for Translational Oncology, German Cancer Research Center partner site Tübingen.

No abstract available

Keywords: hand foot reaction; high-grade glioma; regorafenib.

MeSH terms